Remote-monitoring startup BioIntelliSense received funding from the U.S. Army Medical Research and Development Command (USAMRDC) to see if its wearable sensor “sticker” could be used to detect Covid-19 symptoms early. The Golden, Colo.-based startup, and Royal Philips (NYSE: PHG), received a $2.8 million award to use wearable to identify Covid-19 cases before symptoms appear.

BioIntelliSense received FDA clearance a year ago for a small, adhesive sensor it developed that can monitor a patient’s heart rate, respiratory rate and skin temperature, as well as their gait, body position or coughing. At the beginning of 2020, it struck a partnership with Colorado-based health system UCHealth to use its device leading up to a surgery or for postoperative care.

Now, the companies plan to enroll 2,500 patients into a study, working with the University of Colorado Anschutz Medical Campus, to validate the startup’s BioSticker device for early symptom detection. People who are experiencing Covid-19 symptoms or who had a recent exposure to the disease are eligible to participate.

Lire l’article complet sur : medcitynews.com